1. Retraction Note: A synthetic dsRNA, as a TLR3 pathwaysynergist, combined with sorafenib suppresses HCC in vitro and in vivo
   Yu-Yin Xu et al, 2023, BMC Cancer CrossRef
2. Roles of Toll-Like Receptor 3 in Human Tumors
   Xin Zheng et al, 2021, Frontiers in Immunology CrossRef
3. Innate immunity and hepatocarcinoma: Can toll-like receptors open the door to oncogenesis?
   Jorge André Gomes Lopes, 2016, World Journal of Hepatology CrossRef
4. Gut microbiota mediated molecular events and therapy in liver diseases
   Xiaoqiang Qi et al, 2020, World Journal of Gastroenterology CrossRef
5. Anti-tumor Activity of Toll-Like Receptor 7 Agonists
   Huju Chi et al, 2017, Frontiers in Pharmacology CrossRef
6. Studying the Effect of Downregulating Autophagy-Related Gene LC3 on TLR3 Apoptotic Pathway Mediated by dsRNA in Hepatocellular Carcinoma Cells
   Guilan Wang et al, 2017, Cancer Research and Treatment CrossRef
7. Bufalin Suppresses Migration and Invasion of Hepatocellular Carcinoma Cells Elicited by Poly (I:C) Therapy
   Yinglu Feng et al, 2018, OncoImmunology CrossRef
8. The Interactions Between HBV and the Innate Immunity of Hepatocytes
   Fayed Attia Koutb Megahed et al, 2020, Viruses CrossRef